| Revenue Growth | HIV up 18% to $6.2B; Oncology/Trodelvy up 42% to $506M. |
|---|---|
| Mgmt Confidence | High confidence in 2028 growth despite $1.5B Biktarvy headwind. |
| Demand Visibility | Biktarvy reached 53% US share; Yastugo on track for $1B annually. |
| Margin Trends | Product gross margin 88%; operating margin 50% in Q3 2026. |
| Op. Leverage | Operating margin in top quartile of peer group due to expense discipline. |
| Pricing Power | Higher average realized price in HIV; Medicare price setting limits Biktarvy power. |
| Vol vs Price | Growth driven by higher demand, realized price, and favorable inventory dynamics. |
| Segment Growth | Base business up 16%; Cell Therapy down 18% due to competition. |
| New Clients | Acquiring oral IL-23R inhibitor from Pep-Star; BioNTech and Vera collaborations. |
| Capex & Debt | $1.4B returned to shareholders; $1.4B upfront for Pep-Star and Vera deals. |
| Regulatory | Biktarvy MFP set at $2,600; Anito-cel PDUFA date December 23, 2026. |
| Commentary | Management opposes IRA policies, citing a 'pill penalty' on small molecules. |
| New Launches | Bixlenvo launched August 2026; Anito-cel launch preparations for late 2026. |
Growth
Base business sales rose 16% to $8.2 billion; HIV sales grew 18% to $6.2 billion.
Outlook
Raised 2026 base business revenue guidance to $30.7-$31.0 billion; expects 2028 total revenue growth.
Risks
Biktarvy Medicare price set at $2,600, a 38% discount, causing $1.5 billion 2028 revenue impact.
The company's earnings call, NASDAQ: GILD, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Gilead Sciences, Inc.: key numbers
- Share price
- $167.58Close, Nov 16
- Market cap
- $208B
- Shares outstanding
- 1.24BLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Gilead Sciences, Inc.
All →Gilead Sciences Insider Kelly A. Kramer Sells $1.76M of Stock
Kelly A. Kramer sold 10,376 shares of Gilead Sciences, Inc. at $168.23 to $171.44 a share (average $169.76) in 4 transactions, worth $1.76M in total on Nov 12, 2026. Shares held after the trade: 1,339 (-13.0%).
- Value
- $1.76M
- Shares
- 10,376
- Average price
- $169.76
- Holding change
- -13.0%
- Trade date
- Nov 12, 2026
Gilead Sciences EVP Gen Counsel, Legal & Comp Wettan Keeley M. Cain Sells $558K of Stock
Wettan Keeley M. Cain, EVP Gen Counsel, Legal & Comp, sold 3,399 shares of Gilead Sciences, Inc. at $164.11 a share, worth $558K in total on Nov 6, 2026. Shares held after the trade: 5,360 (-38.8%).
- Value
- $558K
- Shares
- 3,399
- Price
- $164.11
- Role
- EVP Gen Counsel, Legal & Comp
- Holding change
- -38.8%
- Trade date
- Nov 6, 2026
Gilead Sciences Chairman & CEO Daniel Patrick O'Day Sells $19.7M of Stock
Daniel Patrick O'Day, Chairman & CEO, sold 112,429 shares of Gilead Sciences, Inc. at $175.16 to $175.17 a share (average $175.16) in 2 transactions, worth $19.7M in total between Nov 4, 2026 and Nov 5, 2026. Shares held after the trade: 551,683 (-1.7%).
- Value
- $19.7M
- Shares
- 112,429
- Average price
- $175.16
- Role
- Chairman & CEO
- Holding change
- -1.7%
- Trade date
- Nov 4, 2026 to Nov 5, 2026
Gilead Sciences Chairman & CEO Daniel Patrick O'Day Sells $5.33M of Stock
Daniel Patrick O'Day, Chairman & CEO, sold 30,881 shares of Gilead Sciences, Inc. at $167.40 to $175.25 a share (average $172.57) in 6 transactions, worth $5.33M in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 551,683 (-0.4%).
- Value
- $5.33M
- Shares
- 30,881
- Average price
- $172.57
- Role
- Chairman & CEO
- Holding change
- -0.4%
- Trade date
- Oct 30, 2026 to Nov 2, 2026
Gilead Sciences Q3 2026 Results: Net Income $2.43B, Down 20.4% YoY
Gilead Sciences reported total revenues of $8.3 billion for the third quarter of 2026, driven by $8.29 billion in product sales. Despite a profitable third quarter, the company recorded a net loss of $6.05 billion for the first nine months of 2026, primarily due to $11.3 billion in acquired in-process research and development expenses.
- Key figure
- Net income $2.43B · -20.4% YoY
Gilead Sciences Financial Results
Gilead Sciences reported third-quarter 2026 financial results, featuring a 13% increase in total product sales to $8.3 billion, driven by strong performance in its HIV portfolio. The company raised its full-year base business revenue guidance for the second time this year, citing robust demand for Biktarvy and HIV prevention products.
“Gilead delivered an exceptional third quarter, with our strongest year-over-year base business growth in more than a decade, reflecting the strength, breadth and durability of our business.”
Daniel O’Day, Gilead’s Chairman and Chief Executive Officer
“Our performance enabled us to raise our full year base business revenue guidance again this quarter, bringing the total increase to $1.6 billion since the start of 2026.”
Daniel O’Day, Gilead’s Chairman and Chief Executive Officer